Alphamab Oncology

Country
China (Mainland)
Sector
Healthcare
Industry
Biotechnology
Employees
420
Ticker
9966
Exchange
HONG KONG EXCHANGES AND CLEARING LTD
Description
Alphamab Oncology is a biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of innovative cancer therapies. Focusing on the Chinese and global mark...

Alphamab Oncology's Climate Target Data Preview

As of 2024, Alphamab Oncology has disclosed 1 climate targets aimed at reducing its greenhouse gas (GHG) emissions. These include 1 intensity-based target, signaling the company’s commitment to managing and lowering its carbon footprint over time. The targets span various emissions scopes and time horizons, offering insight into Alphamab Oncology ’s climate strategy, ambition level, and alignment with global decarbonization goals.

Target TypeScope of TargetUnitTargetTarget Year
Intensity-based Target
Scope 1 - Total, Scope 2 - Total
Metric Tonnes of CO2 equivalent (mtCO2e) per Renminbi/Chinese Yuan (RMB) of Fixed Assets
Copy restricted. Please purchase to unlock this data.
a
2027
Download Alphamab Oncology's Climate Targets data for free

Create your Tracenable account today and download up to 5 company datasets of your choice for free. No credit card required.

Verified Sources Behind Alphamab Oncology’s Climate Targets Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Alphamab Oncology’s data sources below and access millions more through our Disclosure Search.

a. Alphamab Oncology's ESG Report 2024
Trace every data point back to Alphamab Oncology’s disclosures

Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.

Insights into Alphamab Oncology's Greenhouse Gas Emissions Pathways

As of 2024, Alphamab Oncology has set greenhouse gas (GHG) emissions reduction targets that cover its operational emissions (Scope 1 and 2), but not its value chain emissions (Scope 3). This means its reduction efforts currently focus on direct and purchased energy emissions. a

Does Alphamab Oncology have a target to reduce the emissions from its operations?

As of 2024, Alphamab Oncology has set a target to reduce its operational greenhouse gas (GHG) emissions, specifically those from Scope 1 and Scope 2 sources. a

Alphamab Oncology's most ambitious operational target is to reduce these emissions by 15% by 2027, compared to a baseline of 0 Metric Tonnes of CO2 equivalent (mtCO2e) per Renminbi/Chinese Yuan (RMB) of Fixed Assets in 2024. a

a

Alphamab Oncology's Operational (Scope 1+2) Emissions Pathway

2024202700000BaselineTarget 2027 (-15%)
Want Full Access to Alphamab Oncology's Climate Targets Dataset?
Sign Up